Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $5670.0.

  • Cumberland Pharmaceuticals' Tax Provisions fell 5044.57% to $5670.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$39985.0, marking a year-over-year decrease of 16744.77%. This contributed to the annual value of -$22669.0 for FY2024, which is 14952.92% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Tax Provisions stood at $5670.0, which was down 5044.57% from $5671.0 recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Tax Provisions high stood at $48150.0 for Q4 2022, and its period low was -$56996.0 during Q4 2024.
  • For the 5-year period, Cumberland Pharmaceuticals' Tax Provisions averaged around $7571.2, with its median value being $6938.0 (2023).
  • In the last 5 years, Cumberland Pharmaceuticals' Tax Provisions surged by 28470.76% in 2022 and then tumbled by 32838.6% in 2024.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Tax Provisions stood at $12516.0 in 2021, then soared by 284.71% to $48150.0 in 2022, then tumbled by 48.17% to $24956.0 in 2023, then plummeted by 328.39% to -$56996.0 in 2024, then soared by 109.95% to $5670.0 in 2025.
  • Its Tax Provisions was $5670.0 in Q3 2025, compared to $5671.0 in Q2 2025 and $5670.0 in Q1 2025.